Poor
Partially Aligned
Patient Risk:
Medium
Summary
Some indication-related claims match the provided label (asthma and allergic rhinitis), but multiple other claims about expiration dates and effects after expiration are not supported by the supplied prescribing information, and the label text provided does not address those topics.
Category Scores
Accurate Statements
Singulair is the brand name for montelukast.
Label identifies SINGULAIR as montelukast sodium (active ingredient) in the provided drug context.
Singulair is used for asthma (maintenance).
1.1 Asthma: indicated for prophylaxis and chronic treatment of asthma.
Singulair is used for allergic rhinitis (seasonal or perennial allergies).
1.3 Allergic Rhinitis: relief of symptoms of seasonal allergic rhinitis (≥2 years) and perennial allergic rhinitis (≥6 months).
If asthma symptoms are getting worse, relying on an expired supply to manage breathing is not recommended.
No label support provided in the supplied prescribing information for expired medication or related efficacy concerns; however, this statement is not directly contradicted by the provided label text.
Unsupported Statements
Expiration dates are set to reflect the manufacturer’s guarantee of quality.
The supplied label excerpts do not discuss how expiration dates are set or any concept of manufacturer guarantee of quality.
Past the labeled expiration date, the main concern with montelukast is reduced potency.
The supplied label excerpts do not address potency or effectiveness of montelukast after expiration.
Past the labeled expiration date, montelukast may have changes in how it works in some cases.
No label support in the supplied excerpts for changes in mechanism/behavior after expiration.
Taking an expired medication is usually discouraged.
No label support in the supplied excerpts regarding expired medications.
Montelukast may not work as well after the expiration date if potency has dropped.
The supplied label excerpts do not discuss potency after expiration.
Manufacturers do not guarantee stability beyond the expiration date.
The supplied label excerpts do not discuss stability claims beyond the expiration date.
If used for asthma, weaker dosing from expired montelukast could reduce asthma control.
No label support in the supplied excerpts about dosing changes or effectiveness after expiration.
Reduced potency of montelukast for allergic rhinitis may mean symptoms are less controlled.
No label support in the supplied excerpts about effectiveness after expiration.
Asthma symptoms getting worse may include increased wheezing or shortness of breath.
The supplied label excerpts provided do not list symptom examples for worsening asthma.
Asthma symptoms getting worse may include needing a rescue inhaler more often.
The supplied label excerpts provided do not mention rescue inhaler use or changes in rescue inhaler frequency.
Asthma symptoms getting worse may include chest tightness that is not improving.
The supplied label excerpts provided do not list chest tightness as a worsening symptom.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Neuropsychiatric warnings content (serious NP events; advise patients/caregivers to monitor and discontinue/contact provider for NP symptoms or suicidal thoughts/behavior) is not addressed by the provided claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Multiple claims about expired montelukast efficacy/potency are unsupported by the supplied label excerpts, and the provided claims do not address the label’s serious neuropsychiatric warnings (Warnings and Precautions 5.1), which could affect safe use information completeness.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Several statements (especially those about use/effects of expired montelukast) are not supported by the provided prescribing information, which does not address expiration/stability/potency after expiration.
Suggested Improvement
Limit statements to label-supported content from the provided sections (Indications 1.1 and 1.3 and Warnings 5.1) and remove or reframe expiration-related claims unless the corresponding FDA label sections are supplied.